Projects implemented at MMRI PAS funded by the National Centre for Research and Development (NCBR):
Enabling reliable and rapid preclinical evaluation of macrophage-targeting immune modulatory drug candidates with vascularized in vitro 3D human lung cancer microenvironment models (MAVERIC)
The project is being carried out under the Swiss-Polish Cooperation Programme, co-funded by a specific-purpose grant and supported by Switzerland’s contribution to reducing economic and social disparities within the EU.
Project website: https://www.thelivingnetworks.com/maveric
Project leader: Prof. Tomasz Rygiel, PhD
Project number: SPPW/MAVERIC/0088/2025-00
Total project value: PLN 4,397,980.47
Funding for the entire project: PLN 3,863,947.97, of which:
- from European funds: PLN 3,185,438.71
- from a specific-purpose grant: PLN 678,509.26
Project value for IMDiK PAN: PLN 1,760,824.37
Project funding for IMDiK PAN: 1,754,223.12 PLN, comprising:
- 1,446,181.54 PLN from European funds
- 308,041.58 PLN from a specific-purpose grant
Implementation period: 1 March 2026 – 28 February 2029
Date of contract signing: 17 March 2026
International project carried out in a consortium with: Living Networks Sp. z o.o. (PL – Programme Component Operator), Abbmira Therapeutics AG (CH)
Brief project description: The MAVERIC project aims to overcome resistance to lung cancer treatment by developing new small molecules that reprogramme tumour-associated macrophages, transforming them from defenders of the tumour into its destroyers. To bypass unreliable animal models and accelerate clinical trials, the effectiveness of the therapy will be tested on innovative 3D models of human tumours, which replicate the patient’s real-world environment with the support of artificial intelligence. This work is being carried out by a specialised consortium comprising a biotechnology company, a technology start-up and a medical research institute, opening a new chapter in the effective fight against lung cancer.
The use of engineering and IT methods in prevention, diagnosis and therapy of civilisation diseases - comprehensive development of young researchers’ professional Och! DOK.
Project manager: Joanna Sypecka MD PhD as a representative of MMRI PAS
Project implemented in consortium: The Nalecz Institute of Biocybernetics and Biomedical Engineering PAS (Leader), Institute of Fundamental Technological Research Polish Academy of Sciences
POWER 2014-2020 Operational Programme, implementation period: 2018-2023, project funding: PLN 6 239 475,92
The design of an advanced ocular drug delivery system for the preclinical research market (ANODE).
Project manager: Michał Fiedorowicz MD PhD
The leader X, implementation period: 2019-2022, project funding: PLN 1 499 000
INFRASTART CePT
Project manager: Piotr Kosson Md, PhD as a representative of MMRI PAS
Project implemented in consortium: Medical University of Warsaw (Leader), Institute of Biochemistry and Biophysics Polish Academy of Sciences, Nencki Institute of Experimental Biology, Institute of Fundamental Technological Research Polish Academy of Sciences, Institute of High Pressure Physics of the Polish Academy of Sciences, International Institute of Molecular and Cell Biology, Warsaw University of Technology, Warsaw University
INFRASTARt call, implementation period: 2021-2024, project funding in 2021: 4 647 310,18 zł
